GlassScriptPhysician profile
Michael A Gebel
NPI 1184625329
$7,421.24
in general payments reported to CMS, 2019-2025
47 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $941 · 2021: $521 · 2022: $826 · 2023: $862 · 2024: $1,285 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,018.37 | 2019-2025 | |
| Biogen, INC. | $621.44 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $408.26 | 2019-2025 | Fintepla, Rystiggo |
| Lilly USA, LLC | $358.76 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Lundbeck LLC | $355.80 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $307.33 | 2019-2023 | Aimovig |
| Argenx US, INC. | $302.39 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $298.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $275.38 | 2019-2025 | |
| Sk Life Science, INC. | $274.26 | 2021-2024 | |
| Eisai INC. | $243.53 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $235.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $230.37 | 2019-2025 | Ultomiris |
| Genentech USA, INC. | $200.36 | 2019-2024 | Evrysdi |
| Allergan, INC. | $190.59 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.